65 First-generation (eg, gefitinib and erlotinib) and second-generation (eg, afatinib and dacomitinib) EGFR TKIs have significantly improved PFS, and overall survival in the case of dacomitinib, ...

The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety data that raises the chances of approval when pivotal trials read ...

在1/1.5 mg/kg剂量组，ibi363取得了优异的orr、dcr、pfs、os数据，中位os达15.3个月，提示ibi363通过“pd-1靶向+il-2激活扩增肿瘤特异性t细胞”的免疫检查点 ...

By day 330, LDL cholesterol had declined by 45.6% in those randomized to inclisiran plus usual care whereas there was an increase of 1.4% among those treated with usual care alone (mean difference ...

The PFS and OS benefits with relacorilant were observed across all prespecified subgroups, except for PFS in patients with BRCA1/2-mutant disease (HR, 1.08; 95% CI, 0.49-2.37). The survival benefits ...

Objective The reduction in circulating low-density lipoprotein cholesterol (LDL-c) is the primary aim of lipid-lowering therapies as a method of atherosclerotic cardiovascular disease risk reduction.

The median progression-free survival was 20.6 months in the dostarlimab-niraparib-chemotherapy arm and 19.2 months in the niraparib-chemotherapy arm. Adding dostarlimab to platinum-based ...

Kathleen N. Moore, MD, MS, associate director of clinical research at Stephenson Cancer Center at the College of Medicine of The University of Oklahoma, and coauthors wrote in the presentation, “The ...

主要终点为独立评审委员会根据recist 1.1评估的无进展生存期（pfs），关键次要终点为总生存期（os） 。 本研究呈现预设分析计划的pfs中期分析结果. 研究结果： 截至2024年3月1日， 565例 患者随机分配至a/b组 （各282.5例） 。基线特征均衡。

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Median PFS was not reached for D-VRd, indicating prolonged disease control, while VRd had a median PFS of 49.6 months. The study supports D-VRd as a new standard of care for transplant-ineligible ...